Certain Site-Directed, Nonenzymatically Active Mutants of the Haemophilus influenzae P4 Lipoprotein Are Able To Elicit Bactericidal Antibodies-Reference-Cited by-同舟云学术

Certain Site-Directed, Nonenzymatically Active Mutants of the Haemophilus influenzae P4 Lipoprotein Are Able To Elicit Bactericidal Antibodies

Published:2005-07 Issue:7 Volume:73 Page:4454-4457
ISSN:0019-9567
Container-title:Infection and Immunity
language:en
Short-container-title:Infect Immun

Author:

Green Bruce A.¹,Baranyi Elizabeth¹,Reilly Thomas J.²,Smith Arnold L.²,Zlotnick Gary W.¹

Affiliation:

1. Wyeth Vaccines Discovery Research, 401 N. Middletown Rd., Pearl River, New York 10965

2. Department of Molecular Microbiology and Immunology, University of Missouri Medical School, Columbia, Missouri 65212

Abstract

ABSTRACT The Haemophilus influenzae P4 lipoprotein ( hel ) is a potential component of a nontypeable H. influenzae otitis media vaccine. Since P4 is known to be an enzyme, nonenzymatically active forms of recombinant P4 are required. After site-directed mutagenesis of the hel gene, three of the mutated proteins were shown to be vaccine candidates.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Immunology,Microbiology,Parasitology

Link

https://journals.asm.org/doi/pdf/10.1128/IAI.73.7.4454-4457.2005

Reference16 articles.

1. Bernstein, J. M., H. S. Faden, and P. L. Ogra. 1991. Nasopharyngeal colonization by nontypeable Haemophilus influenzae in children: the effect of serum bactericidal antibody. Otolaryngol. Head Neck Surg.105:406-410.

2. Brinton, C. C., Jr., M. J. Carter, D. B. Derber, S. Kar, J. A. Kramarik, A. C. C. To, and S. W. Wood. 1989. Design and development of pilus vaccines for Haemophilus influenzae diseases. Pediatr. Infect. Dis. J.8(Suppl.):54-61.

3. The e (P4) outer membrane protein of Haemophilus influenzae: biologic activity of anti-e serum and cloning and sequencing of the structural gene

4. A recombinant non-fatty acylated form of the Hi-PAL (P6) protein of Haemophilus influenzae elicits biologically active antibody against both nontypeable and type b H. influenzae

5. Green, B. A., S. B. Olmsted, M. Vazquez, G. Quigley-Reape, and G. W. Zlotnick. 1998. A clinical vaccine formulation for Haemophilus influenzae otitis media containing recombinant P4 and P6 outer membrane proteins, p. 355-362. In M. Tos, J. Thomsen, and V. Balle (ed.), Recent advances in otitis media: proceedings of the fourth extraordinary international symposium. Kugler Publications, Amsterdam, The Netherlands.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microbial 5′-nucleotidases: their characteristics, roles in cellular metabolism, and possible practical applications;Applied Microbiology and Biotechnology;2021-09-27

2. The adhesins of non-typeableHaemophilus influenzae;Expert Review of Anti-infective Therapy;2018-02-21

3. Developing a vaccine to prevent otitis media caused by nontypeable Haemophilus influenzae;Expert Review of Vaccines;2016-03-17

4. Expeditious screening of candidate proteins for microbial vaccines;Journal of Microbiological Methods;2015-09

5. Outer membrane protein P4 is not required for virulence in the human challenge model of Haemophilus ducreyi infection;BMC Microbiology;2014